Key Insights

Highlights

Success Rate

100% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

0.0%

0 terminated out of 17 trials

Success Rate

100.0%

+13.5% vs benchmark

Late-Stage Pipeline

24%

4 trials in Phase 3/4

Results Transparency

0%

0 of 5 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

15Total
Not Applicable (9)
P 2 (2)
P 3 (3)
P 4 (1)

Trial Status

Recruiting6
Completed5
Unknown4
Active Not Recruiting2

Trial Success Rate

100.0%

Benchmark: 86.5%

Based on 5 completed trials

Clinical Trials (17)

Showing 17 of 17 trials
NCT07128199Phase 3Active Not Recruiting

A Study to Assess the Efficacy and Safety of Zipalertinib Versus Placebo for Adjuvant Treatment in Participants With Stage IB-IIIA NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection

NCT07138781Not ApplicableCompleted

Ketamine as an Adjuvant in External Oblique Intercostal Plane Block for Post Thoracotomy Pain

NCT07417397Phase 3Recruiting

Adjuvant TACE in HCC With High-risk Recurrence Factors

NCT07141589Not ApplicableRecruiting

Fentanyl Versus Ketorolac as an Adjuvant to Peribulbar Block for Anterior Segment Surgeries

NCT07139522Not ApplicableRecruiting

Dexamethasone Versus Magnesium Sulphate as an Adjuvant to Bupivacaine in Ultrasound Guided Erector Spinae Plane Block for Postoperative Analgesia in Elective Caesarean Section Under Spinal Anesthesia

NCT06684535Not ApplicableCompleted

Dexmedetomidine as an Adjuvant in External Oblique Intercostal Plane Block for Post Thoracotomy Pain

NCT07047001Phase 2Active Not Recruiting

Vorolanib Monotherapy or in Combination With Toripalimab as Adjuvant Therapy for Patients With Intermediate-high Risk of Recurrence in Renal Cell Carcinoma

NCT06993922Not ApplicableRecruiting

Dexmedetomidine as an Adjuvant to Bupivacaine in Scalp Block Versus Bupivacaine Alone for Postoperative Pain Management in Patients Undergoing Craniotomy

NCT04544202Unknown

Compassionate Use Program BRAF Mutation-positive Patients in the Adjuvant Treatment of Melanoma After Surgical Resection

NCT06667024Not ApplicableCompleted

Dexmedetomidine as an Intrathecal Adjuvant to Hyperbaric Bupivacaine for Postoperative Analgesia in Patients Undergoing Arthroscopic Anterior Cruciate Ligament Reconstruction Surgeries

NCT06403943Phase 4RecruitingPrimary

Efficacy Safety BaiDiZiYin ShenQiYiFei Adjunctive Treatments Pulmonary Tuberculosis

NCT06085417Not ApplicableCompleted

Comparison of the Effects of Dexamethasone and magnesıum Sulphate Used as Adjuvant in Infraclavicular Nerve Block.

NCT04688801Not ApplicableRecruiting

Ajuvant Chemotherapy and Immunotherapy in Patients With Esophageal, Esophageal- Gastric Junction Cancer

NCT04429633Not ApplicableUnknown

Strain vs. Left Ventricular Ejection Fraction-based Cardiotoxicity Prevention in Breast Cancer

NCT00484016CompletedPrimary

Drug Delivery and Toxicities of Adjuvant Chemotherapy in Resected NCSLC

NCT00525642Phase 2Unknown

Study of Suitable Schedule of Docetaxel,Anthracycline and Cyclophosphamide in Adjuvant Therapy of Beast Cancer

NCT00226408Phase 3UnknownPrimary

Standard High-Dose Alpha Interferon Versus Intermittent High-Dose Alpha Interferon

Showing all 17 trials

Research Network

Activity Timeline